Skip to main content
Retour
Watch Compare

Acrivon Therapeutics, Inc.

Qualité des données : 83%
ACRV
Nasdaq Manufacturing Chemicals
1,56 €
▲ 0,03 € (1,63%)
Cap. Boursière: 60,25 M
Prix
1,56 €
Cap. Boursière
60,25 M
Fourchette du Jour
1,44 € — 1,59 €
Fourchette 52 Semaines
1,05 € — 3,56 €
Volume
565 613
Ouverture 1,48 €
Moyenne 50J / 200J
1,63 €
4,58% below
Moyenne 50J / 200J
1,75 €
11,12% below

Quick Summary

Points Clés

Negative free cash flow of -65,33 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-57,36%
En dessous de la moyenne du secteur (-53,41%)
ROIC-48,23%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio8,75
Interest CoverageN/A

Valorisation

PE (TTM)
-0,77
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,47
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,8 -1,5
P/B 0,5 1,6
ROE % -57,4 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

CNCR CNCR
1,14% weight
BRSIX BRSIX
0,15% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -77,91 M
ROE -57,36% ROA -51,27%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -65,33 M
ROIC -48,23% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,75
Interest Coverage N/A Asset Turnover N/A
Working Capital 115,47 M Tangible Book Value 128,60 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,77 Forward P/E N/A
P/B Ratio 0,47 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -108,44%
Market Cap 60,25 M Enterprise Value 24,84 M
Per Share
EPS (Diluted TTM) -2,02 Revenue / Share N/A
FCF / Share -1,69 OCF / Share -1,64
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 83,86%
SBC-Adj. FCF -80,63 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue — — — —
Net Income -77,91 M -80,56 M -60,39 M -31,17 M
EPS (Diluted) -2,02 -2,38 -2,74 -7,56
Gross Profit — — — —
Operating Income -84,11 M -89,20 M -67,10 M -32,66 M
EBITDA — — — —
R&D Expenses 59,99 M 63,99 M 46,02 M —
SG&A Expenses — — — —
D&A — — — —
Interest Expense — — — —
Income Tax 0,0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 129,72 M 196,59 M 138,27 M 181,23 M
Total Liabilities 17,20 M 19,80 M 17,07 M 10,75 M
Shareholders' Equity 112,52 M 176,79 M 121,20 M 170,48 M
Total Debt — — — —
Cash & Equivalents 41,50 M 39,82 M 36,02 M 29,52 M
Current Assets 120,45 M 181,63 M 129,69 M 132,10 M
Current Liabilities 15,66 M 17,21 M 13,30 M 6,52 M